uniQure

Today we reported our financial results for the second quarter of 2025 and highlighted recent progress across our business. https://lnkd.in/et7xv4vF

Our uniQure team was privileged to attend this past weekend’s #HDSAConvention, a fantastic opportunity to connect with and learn from the #huntingtonsdisease community. We return home inspired by the courage and resiliency of the HD community and excited to continue our work to bring a potentially transformative #genetherapy to families in need.

Our uniQure team was privileged to attend this past weekend’s #HDSAConvention, a fantastic opportunity to connect with and learn from the #huntingtonsdisease community. We return home inspired by the courage and resiliency of the HD community and excited to continue our work to bring a potentially transformative #genetherapy to families in need.

The powerful candle-lighting ceremony at tonight’s HDSA National Awards Dinner & Gala was the emotional pinnacle of an inspiring evening, lighting the room with love and hope in memory of those lost and in honor of all those fighting against #huntingtonsdisease. #HDSAConvention

A full house at #HDSAConvention for today's Clinical Trial Showcase, which included a fireside chat between David Margolin, the program lead for our #huntingtonsdisease clinical program, and Dr. Victor Sung, director of the UAB HD clinic and a PI in the trial. The two discussed the encouraging data in the AMT-130 clinical trial and the next steps for the program. They also expressed their deep appreciation for all the brave people who participate in clinical trials and make cutting-edge research like this possible. "I hope you all agree that this is an exciting time in research in HD, and there are some exciting updates with the AMT-130 program," said Dr. Sung. "For me, this falls under this umbrella of cautious optimism, which, in the wake of failures that we've had in HD trials over many years, I will certainly take."

Our #HDSAConvention booth is open! Come drop by this weekend to say hello, grab some snacks, and learn more about our AMT-130 #genetherapy program in #huntingtonsdisease.

We're thrilled to be heading to Indy as a Gold Sponsor of this year's #HDSAConvention, where we'll have a fantastic cross-functional team on hand to attend the sessions, support the #huntingtonsdisease community, and share information about our AMT-130 #genetherapy program.

Very excited to welcome Kylie to uniQure as we gear up for the launch of AMT-130 in Huntington’s disease — a first-in-class gene therapy and a potential turning point for patients and their families. #huntingtonsdisease

This week we announced the appointment of Kylie O’Keefe as our Chief Customer and Strategy Officer. She will lead the development and execution of uniQure’s global commercialization strategy for AMT-130, our investigational #genetherapy for the treatment of #huntingtonsdisease.  Welcome, Kylie!

"What we are developing are one-time administered, potentially curative therapies to provide hope to these patients where they don't have hope; they simply don't have any therapeutic alternatives. That is an enormous opportunity to really transform medicine as we know it today." CEO Matthew Kapusta talks about uniQure's mission to transform the lives of patients through the power of genetics, and how that mission drives who we are at uniQure. #genetherapy https://lnkd.in/gviFQmXw